Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)

Recruiting

Phase 1

Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)

Sponsor:

City of Hope Medical Center

Code:

NCT05371132

Conditions

Metastatic Malignant Solid Neoplasm

Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Positron Emission Tomography

Stereotactic Body Radiation Therapy

Zirconium Zr 89-Df-Crefmirlimab

Intensity Modulated Radiation Therapy

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-07-02. This information was provided to ClinicalTrials.gov by City of Hope Medical Center on 2025-01-14.